CHICAGO, IL and Research Triangle Park, NC - September 23, 1998
Integrated Genomics, Inc. (IG) announced today that it entered into a research collaboration with Glaxo Wellcome (NYSE: GLX), covering the development and licensing of metabolic bioinformatics software. Under the terms of the two-year agreement, Glaxo Wellcome will obtain access to EMP, the database of enzymatic reactions and pathways and to the query software being developed by IG.
EMP is the integrative parts of IG's bioinformatics discovery platform for functional annotation of sequence data, metabolic reconstruction and modeling. With more than 21,000 entries, the database represents the most comprehensive computerized source for enzymatic reactions in the world. The pathway module of EMP is designed to facilitate the assembly of protein functions into "wiring diagrams" of cellular metabolism. EMP is the major tool used for metabolic design and engineering based on sequence data. IG's experts will cooperate with Glaxo Wellcome to install and customize the software for their internal bioinformatics environment.
"We are happy to provide our expertise in bioinformatics for Glaxo Wellcome, known for its innovative research approaches", said Robert Haselkorn, President and Chairman of the Board of Integrated Genomics. "Metabolic engineering is becoming a mainstream technology in life science, destined to bridge the gap between DNA sequence information and industrial applications, such as new drug discovery. The current agreement with a leader of the pharmaceutical industry is very encouraging in our effort to develop the first universal software for encoding and modeling metabolism".
About Integrated Genomics
Chicago-based Integrated Genomics provides all levels of analysis of bacterial and fungal genomes, from high-throughput sequencing to sophisticated bioinformatics. The company is a leader in sequence-based metabolic reconstruction and pathway design. An integration of reconstructions of more than 170 proprietary and public genomes, MicobAce™, will be released later this year.
Dr. Robert Haselkorn
Integrated Genomics, Inc.